Research Library
Curated Studies & Clinical Data
A growing library of peer-reviewed studies, clinical trial data, and systematic reviews organized by compound. Every citation is linked to its primary source.
Anti-Obesity Medications in Longevity and Aesthetic Medicine
Journal of clinical medicine, 2026;15(15)
Semaglutide and Liraglutide Modulate Oxidative Stress and Wound Repair in Normal Human Skin Cells Exposed to an In Vitro Diabetic-like Environment
International journal of molecular sciences, 2026;27(15)
Can Carica papaya Serve as an Adjunct to Semaglutide in Mitigating Diabetes-Induced Testicular Injury Through Modulation of Oxidative Stress, Inflammation, Apoptosis, and the miR-34c/miR-155-SIRT1/FOXO1 Axis? An Experimental and Chem-Bio-Informatics Study
International journal of molecular sciences, 2026;27(15)
GLP-1-based incretin therapy is associated with lower incident Alzheimer’s disease and cardiorenal events in adults with documented neuropsychiatric, cognitive, or sensory risk
Biology methods & protocols, 2026;11(1):bpag043
Discontinuation of Semaglutide Therapy for Obesity Management
JAMA network open, 2026;9(8):e2631371
Suspected Biphasic Anaphylaxis Following the First Known Dose of Tirzepatide: A Case Report and Brief Review of Reported Hypersensitivity Reactions
Cureus, 2026;18(8):e113910
Tirzepatide in recurrent hypertriglyceridemia-mediated pancreatitis and type 2 diabetes: a case report
Cardiovascular diabetology. Endocrinology reports, 2026;12(1)
Real-world evaluation of the effectiveness and safety of tirzepatide in patients with obesity: a prospective study
Clinical nutrition ESPEN, 2026;:105005
Semaglutide ameliorates traumatic sepsis-induced cardiac injury by activating the March5-ACSL4 axis to suppress ferroptosis
Free radical biology & medicine, 2026
Safety of glucagon-like peptide-1 receptor agonists in neuroendocrine neoplasms
European journal of endocrinology, 2026
MASLD and Cardiovascular Risk: Mechanisms and Implications for Clinical Practice
Current hypertension reports, 2026;28(1)
Ability of Adults to Correctly Use Grey Market Peptide Semaglutide GLP-1 Receptor Agonists Acquired Without a Prescription
Public health reports (Washington, D.C. : 1974), 2026;:333549261464876
Atypical Anorexia Nervosa Developed in a Patient with Severe Obesity and Type 2 Diabetes Following Sleeve Gastrectomy and Postoperative Treatment with Semaglutide and Tirzepatide
Internal medicine (Tokyo, Japan), 2026
Structured Exercise During and After Incretin-Based Pharmacotherapy Discontinuation: A Narrative Review of Mechanisms, Evidence, and Prescription Guidance
Healthcare (Basel, Switzerland), 2026;14(15)
Incretin-Based Therapies Versus Bariatric and Metabolic Surgery for Obesity and Type 2 Diabetes Mellitus: A Head-to-Head Systematic Review of Glycaemic, Cardiovascular, Hepatic, Weight, and Quality-of-Life Outcomes
Cureus, 2026;18(8):e113777
Tirzepatide and SGLT2 Inhibitors for Heart Failure With Preserved Ejection Fraction and Obesity: Entering a New Cardiometabolic Therapeutic Era
Endocrinology, diabetes & metabolism;9(5):e70298
Effectiveness & safety of semaglutide in weight reduction in obese nondiabetic patients: A systematic review and meta-analysis
Medicine;105(31):e49986
[An historical overview of GLP-1/GIP incretins. From hormone to “swiss-army knife” medications]
Biologie aujourd'hui, 2026;220(1-2):9-24
Hypertensive disorders of pregnancy and GLP-1 receptor agonist timing: a systematic review and meta-analysis
Endocrine, 2026;91(1)
Early changes in renal function do not appear to mediate cardiovascular risk with dapagliflozin plus semaglutide: a real-world observational hypothesis-generating cohort study
Expert review of cardiovascular therapy, 2026